Condensed Consolidated Statements of Cash Flows - USD ($)	6 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Operating activities
Net loss	$ (3,292,481)	$ (3,451,317)
Adjustments to reconcile net loss to net cash and cash equivalents used in operating activities:
Depreciation and amortization	1,426,172	767,135
Bad debt expense		50,000
Reserve for contract asset	960,000
Stock-based compensation	749,736	1,504,586
Release of valuation allowance on deferred tax assets	(4,085,000)
Changes in operating assets and liabilities:
Accounts receivable	(2,096,665)	(513,749)
Inventories	(5,673,609)	(1,189,559)
Prepaid expenses and other current assets	(481,817)	9,895
Lease and other assets	77,689	(7,310)
Intangible assets		65,980
Accounts payable, accrued expenses and other current liabilities	(1,008,698)	1,651,129
Net cash used in operating activities	(13,424,673)	(1,113,210)
Investing activities
Acquisition of property, plant and equipment	(211,347)	(485,191)
Additional patents	(71,893)	(75,105)
Cash from acquisition of Solsys Medical, LLC	5,525,601
Net cash provided by (used in) investing activities	5,242,361	(560,296)
Financing activities
Proceeds from notes payable	18,750,000
Repayments of notes payable	(3,819,940)
Stock registration fees	(1,361,392)
Proceeds from exercise of stock options	1,175,084	867,337
Net cash provided by financing activities	14,743,752	867,337
Net increase (decrease) in cash and cash equivalents	6,561,440	(806,169)
Cash and cash equivalents at beginning of year	7,842,403	10,979,455
Cash and cash equivalents at end of year	14,403,843	10,173,286
Cash paid for:
Interest	814,577
Income taxes	550	13,273
Transfer of inventory to property, plant and equipmment for consignment of product	1,940,179	497,917
Stock issued for the acquisition of Solsys Medical, LLC	$ 108,643,710